Pazopanib and Abexinostat for Kidney Cancer
Phase 3
413
about 10 years
18+
14 sites in AZ, CA, KY +8
What this study is about
Researchers are testing whether abexinostat, pazopanib, or a placebo improves outcomes in people with locally advanced or metastatic kidney cancer. The trial will last 3636 days (about 10 years) and involve about 413 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Placebo
- 2.Take Abexinostat
- 3.Take Pazopanib
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
pazopanib
oral (Oral Tablet)
Primary: Progression-free survival (PFS)
Secondary: Adverse events by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5, DOR by RECIST version 1.1 in cross-over patient population, Duration of response (DOR), Mean change from Baseline in Functional Assessment of Cancer Therapy Kidney System Index (FKSI-19) scores, Mean change from Baseline in Functional Assessment of Chronic Illness Therapy (FACIT-F) scores, ORR by RECIST version 1.1 in cross-over patient population, Objective response rate (ORR), Overall survival (OS)
Oncology